Answers are grounded in this paper and cite their sources.
Immune checkpoint inhibitor combinations have improved outcomes in hepatocellular carcinoma, but durable benefit remains uneven and the optimal integration of locoregional therapy is unresolved. Local interventions can release tumor antigens, alter vascular and stromal barriers, and recruit innate and adaptive immune cells. These effects can coexist with tissue repair, angiogenic signaling, myeloid recruitment, and renewed checkpoint expression. This narrative review examines therapeutic timing for clinicians and translational researchers. A targeted PubMed search, publisher reports, and reference checking informed the revision; studies were selected for relevance to human immune kinetics, clinical schedules, safety, and biomarker validation. This review compares thermal ablation, transarterial chemoembolization, yttrium-90 radioembolization, irreversible electroporation, and stereotactic body radiotherapy; evaluates checkpoint inhibition before, after, or overlapping local treatment; and assesses candidate scheduling biomarkers. Human studies document selected immune changes, while phase 3 trials show that some treatment combinations extend progression-free survival. However, these trials do not isolate timing, and observational schedule comparisons cannot establish a causal advantage or a universal interval. A modality- and patient-specific hypothesis is therefore discussed in which measured immune state and hepatic reserve could inform future scheduling trials. No biomarker-triggered schedule has demonstrated clinical utility. Serial tissue and blood sampling, pharmacokinetic assessment, and schedule-specific randomization are needed before an immunogenic window can guide routine care.
No takes yet. Share an insight, caveat, or question.
Guo et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: